2nd Annual MarketsandMarkets

Biomarker and Companion Diagnostics Conference - East Coast Edition

20th - 21st June 2024

Hilton Boston Logan Airport, One Drive, Boston, MA 02128, USA

From Discovery to Diagnosis: Bridging the Biomarker Gap

MarketsandMarkets presents the Immunobio Series, an extraordinary set of conferences taking place on 20-21 June 2024 in Hilton Boston Logan Airport, One Drive, Boston, MA 02128, USA.

MarketsandMarkets 5th Annual Biomarker and Companion Diagnostics Conference:

Immerse yourself in the realm of biomarkers at our flagship event, where industry leaders and experts converge to propel innovation in healthcare, diagnostics, and personalized medicine. This conference serves as a dynamic platform for collaboration, knowledge sharing, and exploration of cutting-edge biomarker research and applications. Esteemed keynote speakers will deliver groundbreaking insights into the latest developments and future prospects of biomarker research, making it a hub for fostering collaboration and driving innovation. Anticipated as the largest industry-led meeting, this conference unites over 200 senior decision-makers in the biomarker and CDx field, providing unparalleled insights. Attendees will gain actionable insights to identify biomarker and CDx development advancements across oncology and non-oncology indications, including NASH, Alzheimer’s, and Parkinson’s, revolutionizing personalized medicine pipelines. The summit will address challenges in analytical validation, explore regulatory landscapes, and leverage bioinformatics and AI for enhanced biomarker discovery. The 2024 summit promises an exclusive opportunity for knowledge sharing and networking among industry leaders, making a marked difference in patient outcomes.

Tag Line
30+ experts from academia and industry will be presenting their current work in Biomarkers, Latest updates on regulatory guidelines and approvals, Cancer biomarker validation for clinical application, Biomarkers and Personalized Medicine, Impact of Big data in translational biomarker research and Future of Companion Diagnostics
Tag Line
Opportunity to develop long-lasting business relationships and networking opportunities with researchers, scientists, clinicians, academicians and professionals from Pharmaceutical companies, Bio-pharma companies, Universities, and Research institutes.
Tag Line
Over 20 presentations, round-tables, and panel discussions focused on the key opportunities and challenges in biomarker research, from precision medicine and companion diagnostics through to digital biomarkers and clinical trials.

MarketsandMarkets 7th Annual Next Gen Immuno-Oncology Conference:

Explore the forefront of cancer treatment at our flagship Immuno-Oncology Conference. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions. With more than 40 speakers across the world from pharma, biopharma and biotech companies, the congress will discuss the latest updates and share insights in development of ADC’s, Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors and Cellular Therapy shaping the future of immuno-oncology.

Join us for this transformative event, where innovation meets collaboration, shaping the future of healthcare and biotechnology.

CO-LOCATED CONFERENCES

7th Annual MarketsandMarkets Next-Gen Immuno-Oncology Conference

WHAT TO EXPECT

  • Biomarker Discovery Techniques: Explore novel strategies, including genomics, proteomics, metabolomics, and bioinformatics, to identify cutting-edge biomarkers.
  • Precision Medicine Tailoring: Understand the pivotal role of biomarkers in customizing treatments for individual patients, enhancing efficacy, and minimizing side effects.
  • Rigorous Biomarker Validation: Learn strategies and overcome challenges in validating biomarkers for clinical use, ensuring robust and reliable results.
  • Clinical Applications Across Disorders: Delve into biomarker applications in cancer, immunology, neurodegenerative disorders, and cardiovascular conditions for targeted advancements.
  • Bioinformatics and AI Analysis: Attend workshops and sessions on biomarker data analysis, employing machine learning and artificial intelligence approaches for comprehensive insights.
  • Biomarker-Based Diagnostics Development: Gain insights into the development and commercialization of diagnostic tests and platforms based on biomarkers.
  • Regulatory Frameworks for CDx: Stay updated on current regulatory frameworks for CDx development, facilitating smoother approvals and applications.
  • Expanding Biomarker Testing Access: Navigate reimbursement landscapes through cross-sector collaborations to widen access to biomarker testing.
  • Innovative Strategies in CDx Development: Implement new CDx strategies to bring innovative therapies to the clinic, ensuring effective market access in line with global trends.
  • Collaboration for Advancement: Explore sessions on fostering collaboration among academia, industry, and government agencies to drive biomarker research forward.

  1. Cutting-Edge Insights: Access the latest advancements in biomarker discovery, precision medicine, and clinical applications spanning cancer, immunology, neurodegenerative disorders, and cardiovascular biomarkers.
  2. Innovative Immunotherapy: Dive into immune-oncology projects, exploring antibodies, cellular therapy, and immune checkpoint research. Contribute to interactive discussions, share your work, and stay updated on cutting-edge technologies and platforms.
  3. Networking and Collaboration: Connect with industry leaders, researchers, and peers. Foster collaborations, engage in thought-provoking discussions, and explore partnership opportunities.
  4. Professional Development: Enhance your skills with workshops on biomarker data analysis, machine learning, and artificial intelligence applications. Learn best practices and methodologies for biomarker and IO research.
  5. Practical Applications: Discover how research translates into real-world applications. Explore exhibitor showcases, demonstrations, and case studies, gaining insights into the latest tools and technologies.
  6. Personal and Industry Growth: Step out of your comfort zone, engage in interactive roundtables, and contribute to key discussions. Elevate your personal and professional growth within the dynamic fields of biomarker research and immunotherapy.

Engage in groundbreaking research, expand your network, and drive innovation at the Immunobio Series, where science meets collaboration.

Researchers, scientists, clinicians, academicians and professionals from Pharmaceutical companies, Bio-pharma companies & Universities and Research institutes working in:

  • Biomarker discovery/development
  • Translational research
  • Clinical Biomarker
  • Biomarkers in IO and Neurological disorders
  • Imaging Biomarkers
  • Pathology
  • Companion Diagnostics
  • Biomarker Imaging
  • Proteomics Biomarkers
  • Experimental Medicine
  • Data Science
  • Biomarkers in Clinical Discovery
  • Immuno-oncology/Neuroscience Drug Discovery
  • Diagnostic Biomarkers development
  • Personalized Medicine
  • Immunology Biomarkers

CONFERENCE AGENDA

Registration

08:15 - 08:50

Opening Remarks from the Chairperson

08:55 - 09:00

Keynote Presentation- How to continue running clinical trials in the EU under IVDR: A pharma company’s perspective

Lindsay Darling

Lindsay Darling, Director, Companion Diagnostics Portfolio Management & Operations, Regeneron

09:00 - 09:30

Transforming Oncology with Predicine’s Liquid Biopsy Solutions

Alexander Kuklin

Alexander Kuklin, Vice President CDx and BioPharma Partnerships, Predicine

09:30 - 10:00

Enhanced Biomarker Discovery and Validation Using TMT® Proteomics

Richard Dennis

Richard Dennis, Chief Commercial Officer, Proteome Sciences

10:00 - 10:30

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:30 - 11:15

Proteo-metabolomics as a source of predictive biomarkers

Samir Hanash

Samir Hanash, Director, McCombs Institute for Cancer Detection and Treatment, MD Anderson Cancer Center

11:15 - 11:45

Targeted Monoclonal Antibody development for Therapeutic and Diagnostic applications in Oncology.

Ginette Serrero

Ginette Serrero, CEO, Precision Antibody, A&G Pharmaceutical, Inc. | Precision Antibody

11:45 - 12:15

Strategic Approaches to Biomarker Integration in Clinical Research

Alok Pandey

Alok Pandey, Vice President, Biomarker & Translational Science, PBL Assay Science

12:15 - 12:45

Tumor Immune Microenvironment: A Novel Biomarker to Predict Immunotherapy Outcomes

Tyler Nielsen

Tyler Nielsen, Sr Scientist, Oncocyte Corporation

12:45 - 13:15

Lunch and Poster Presentation | One-to-One Networking Meetings

13:15 - 14:15

Biomarkers and Pharmacokinetics of Monoclonal Antibodies

Ravinder Singh

Ravinder Singh, Professor of Laboratory Medicine and Pathology, Mayo Clinic

14:15 - 14:45

A Public-Private Consortium for Evaluation of Assays for Non-invasive Tumor Gene Expression Profiling

Althea Lang

Althea Lang, Scientific Project Manager, Translational Science, Foundation for the National Institutes of Health

14:45 - 15:15

Dissection of the Tumor Microenvironment Using Spatial Transcriptomics and Deep Learning

Mario Flores

Mario Flores, Assistant Professor, Department of Biomedical Engineering, The University of Texas at San Antonio

15:15 - 15:45

Afternoon Refreshments and Poster Presentation | One-to-One Networking Meetings

15:45 - 16:30

Multiplexed cytokine measurements in culture supernatants upon ex vivo stimulation of human PBMCs to assess cellular immune response in vaccine studies

Bhaskarjyoti Sarmah

Bhaskarjyoti Sarmah, Associate Scientific Director, Clinical Biomarkers, Moderna

16:30 - 17:00

Detection of ADA-bound protein by acid dissociation

Yi-Ya Fang

Yi-Ya Fang, Senior advisor, Eli Lilly and Company

17:00 - 17:30

Closing Remarks from the Chairperson

17:30 - 17:30

Registration

08:15 - 08:55

Opening Remarks from the Chairperson

Rakesh Dixit

Rakesh Dixit, CEO, Bionavigen

08:55 - 09:00

Keynote Presentation- Anchored Immunotherapy as a Better Approach for Delivery of Immuno-oncology Agents

Howard Kaufman

Howard Kaufman, President and CEO, Lecturer, Ankyra Therapeutics, Harvard Medical School

09:00 - 09:30

Landscape change in melanoma immunotherapy. Déjà vu or revolution?

Takami Sato

Takami Sato, Professor of Medical Oncology Research Director, Thomas Jefferson University

09:30 - 10:00

SanyouBIO One-Stop Solution for Bispecific antibody and ADC

Lanye Huang

Lanye Huang, Business Development Executive/ Senior BD Manager, SanyouBio

10:00 - 10:30

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:30 - 11:15

Enhanced Multiplex IHC Technology for Precision Oncology

Aurélie Auguste

Aurélie Auguste, Director, Translational Data Analysis, Veracyte

11:15 - 11:45

SUPLEXA therapeutic cells, a clinically derisked cell therapy platform with unique mechanisms of action for treating solid cancers

Frank Borriello

Frank Borriello, Founder and CEO, Alloplex Biotherapeutics

11:45 - 12:15

Development of methylation and mutation panel for colorectal cancer

Collin Hudzik

Collin Hudzik, Scientist, EpigenDx

12:15 - 12:45

Next generation translational research platforms for cell therapy in cancer

Aaron Goldman

Aaron Goldman, Faculty and Instructor in Medicine, Harvard Medical School

12:45 - 13:15

Lunch and Poster Presentation | One-to-One Networking Meetings

13:15 - 14:15

A Novel B7 Checkpoint Axis for Therapeutic Targeting in Cancer

Leena Gandhi

Leena Gandhi, Chief Medical Officer, NextPoint Therapeutics

14:15 - 14:45

Immune stimulation of myeloid cells for cancer therapy

Christopher Garris

Christopher Garris, Assistant Professor of Pathology, Massachusetts General Hospital, Harvard Medical School

14:45 - 15:15

Preliminary results of a Phase 1 study of Decoy20, an intravenous, killed, multiple immune receptor agonist bacterial product in patients with advanced solid tumors.

Roger Waltzman

Roger Waltzman, Chief Medical Officer, Indaptus Therapeutics

15:15 - 15:45

Afternoon Refreshments and Poster Presentation | One-to-One Networking Meetings

15:45 - 16:30

Enhancing TCR-T Activity for Solid Tumors through Synthetic Biology and Gene Editing

Allison Drain

Allison Drain, Preclinical Development, Affini-T Therapeutics

16:30 - 17:00

Panel Discussions - Adverse Events and Safety Management: Review potential side effects of immunotherapies and best practices for managing them.

Roger Waltzman

Roger Waltzman, Chief Medical Officer, Indaptus Therapeutics

Rakesh Dixit

Rakesh Dixit, CEO, Bionavigen

Christopher Garris

Christopher Garris, Assistant Professor of Pathology, Massachusetts General Hospital, Harvard Medical School

Takami Sato

Takami Sato, Professor of Medical Oncology Research Director, Thomas Jefferson University

Raluca Budiu-Predoiu

Raluca Budiu-Predoiu, Director, Companion Diagnostics Strategy Lead, , Abbvie

17:00 - 17:30

Closing Remarks from the Chairperson

Rakesh Dixit

Rakesh Dixit, CEO, Bionavigen

17:30 - 17:30

Registration

08:15 - 08:55

Opening Remarks from the Chairperson

Mario Flores

Mario Flores, Assistant Professor, Department of Biomedical Engineering, The University of Texas at San Antonio

08:55 - 09:00

Keynote Presentation - Challenges and Strategies in CDx Development for Supporting Clinical Trials for Innovative Medicine

David Yu

David Yu, Director, Precision Medicine and Translational Medicine, Bristol Myers Squibb

09:00 - 09:30

From Assay Development to Commercialization: CDx Strategy in Genetics Medicine

Melis McHenry

Melis McHenry, Associate Director, Precision Medicine CDx, Regeneron

09:30 - 10:00

Research and Startups Combining Biomarkers, Devices and Algorithms for Personalized Diagnosis and Intervention

Vaibhav Saini

Vaibhav Saini, Senior Commercialization Manager, Northeastern University

10:00 - 10:30

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:30 - 11:15

The Evolving Landscape of Global Deployment of Liquid Biopsy in Enabling Precision Medicine-Driven Biomarker Focused Drug Development

Zheng Feng

Zheng Feng, Head, Molecular Biomarkers & Genomics, EMD Serono

11:15 - 11:45

Clinical decision rule guided cut-point selection for companion diagnostic (CDx) development

Wenting Wang

Wenting Wang, Oncology Biomarker Statistics Team Lead, Sanofi

11:45 - 12:15

Why you should be concerned about sample preanalytics (A.K.A. garbage in, garbage out)

Russell Weiner

Russell Weiner, Head Oncology and Cell Therapy Clinical Biomarker Sciences, Takeda

12:15 - 12:45

Tailored treatments, artificial intelligence, and the next era of Precision Medicine

Amanda Acerbi

Amanda Acerbi, Precision Medicine Global Director, Janssen

12:45 - 13:15

Lunch and Poster Presentation | One-to-One Networking Meetings

13:15 - 14:15

Operational Strategies for Precision Oncology Trials

Ariel Lefkovith

Ariel Lefkovith, Manager, Biomarker Operations, Repare Therapeutics

14:15 - 14:45

Panel Discussion: Opportunities and Challenges in Biomarker Testing: Comparing Oncology and Non-Oncology Perspectives

Joseph Ferrara

Joseph Ferrara, Chief Strategy Officer, Veranex

Ginette Serrero

Ginette Serrero, CEO, Precision Antibody, A&G Pharmaceutical, Inc. | Precision Antibody

Zheng Feng

Zheng Feng, Head, Molecular Biomarkers & Genomics, EMD Serono

Mario Flores

Mario Flores, Assistant Professor, Department of Biomedical Engineering, The University of Texas at San Antonio

Melis McHenry

Melis McHenry, Associate Director, Precision Medicine CDx, Regeneron

Amanda Acerbi

Amanda Acerbi, Precision Medicine Global Director, Janssen

Vaibhav Saini

Vaibhav Saini, Senior Commercialization Manager, Northeastern University

14:45 - 15:30

Closing Remarks from the Chairperson

Mario Flores

Mario Flores, Assistant Professor, Department of Biomedical Engineering, The University of Texas at San Antonio

15:30 - 15:30

Registration

08:15 - 08:55

Opening Remarks from the Chairperson

Rakesh Dixit

Rakesh Dixit, CEO, Bionavigen

08:55 - 09:00

Keynote Presentation - Challenges and Opportunities for the development of ADCs, bispecific immunomodulatory therapies, and combination.

Rakesh Dixit

Rakesh Dixit, CEO, Bionavigen

09:00 - 09:30

ProtoNKTM Cells from Pluripotent Stem Cells: Therapeutics for All Patients

Allen Feng

Allen Feng, Founder and Chief Scientific Officer, HebeCell Corporation

09:30 - 10:00

Polyploid giant cancer cells: the senescent actuators and evil root of cancer recurrence

Shriya Joshi

Shriya Joshi, Scientist, small molecule drug discovery, Bristol Myers Squibb

10:00 - 10:30

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:30 - 11:15

Intrinsic differences in tumor biology due to post translation modifications and protein-protein interactions lead to racial disparity in breast cancer

Chakravarthy Garlapati

Chakravarthy Garlapati, Senior Scientist, (Molecular and Cell Pharmacology), Alkermes

11:15 - 11:45

Novel antibody-enabled targeted protein stabilization (TPS2) that augments anti-tumor immune response by delivering Cbl-b inhibitor to immune cells while blocking checkpoint molecule, PD1

Joanne Lim

Joanne Lim, Associate Director, Immunology, Orum Therapeutics

11:45 - 12:15

Liquid biopsy – a step closer to realizing the power of precision oncology

Raluca Budiu-Predoiu

Raluca Budiu-Predoiu, Director, Companion Diagnostics Strategy Lead, , Abbvie

12:15 - 12:45

Panel Discussion: Immunotherapy Frontiers: Integrating Precision Immunology, Cancer Microbiome, and CAR-T Therapies for Tailored Patient Care

Takami Sato

Takami Sato, Professor of Medical Oncology Research Director, Thomas Jefferson University

Aaron Goldman

Aaron Goldman, Faculty and Instructor in Medicine, Harvard Medical School

Shriya Joshi

Shriya Joshi, Scientist, small molecule drug discovery, Bristol Myers Squibb

Chakravarthy Garlapati

Chakravarthy Garlapati, Senior Scientist, (Molecular and Cell Pharmacology), Alkermes

12:45 - 13:15

Lunch and Poster Presentation | One-to-One Networking Meetings

13:15 - 14:15

SPEAKERS

Melis McHenry

Melis McHenry

Associate Director, Precision Medicine CDx, Regeneron

Alok Pandey

Alok Pandey

Vice President, Biomarker & Translational Science, PBL Assay Science

Joseph Ferrara

Joseph Ferrara

Chief Strategy Officer, Veranex

Samir Hanash

Samir Hanash

Director, McCombs Institute for Cancer Detection and Treatment, MD Anderson Cancer Center

Vaibhav Saini

Vaibhav Saini

Senior Commercialization Manager, Northeastern University

Ginette Serrero

Ginette Serrero

CEO, Precision Antibody, A&G Pharmaceutical, Inc. | Precision Antibody

Richard Dennis

Richard Dennis

Chief Commercial Officer, Proteome Sciences

Russell Weiner

Russell Weiner

Head Oncology and Cell Therapy Clinical Biomarker Sciences, Takeda

Ariel Lefkovith

Ariel Lefkovith

Manager, Biomarker Operations, Repare Therapeutics

Ravinder Singh

Ravinder Singh

Professor of Laboratory Medicine and Pathology, Mayo Clinic

Wenting Wang

Wenting Wang

Oncology Biomarker Statistics Team Lead, Sanofi

Alexander Kuklin

Alexander Kuklin

Vice President CDx and BioPharma Partnerships, Predicine

Mario Flores

Mario Flores

Assistant Professor, Department of Biomedical Engineering, The University of Texas at San Antonio

Zheng Feng

Zheng Feng

Head, Molecular Biomarkers & Genomics, EMD Serono

Amanda Acerbi

Amanda Acerbi

Precision Medicine Global Director, Janssen

Althea Lang

Althea Lang

Scientific Project Manager, Translational Science, Foundation for the National Institutes of Health

Bhaskarjyoti Sarmah

Bhaskarjyoti Sarmah

Associate Scientific Director, Clinical Biomarkers, Moderna

Lindsay Darling

Lindsay Darling

Director, Companion Diagnostics Portfolio Management & Operations, Regeneron

David Yu

David Yu

Director, Precision Medicine and Translational Medicine, Bristol Myers Squibb

Yi-Ya Fang

Yi-Ya Fang

Senior advisor, Eli Lilly and Company

Tyler Nielsen

Tyler Nielsen

Sr Scientist, Oncocyte Corporation

ENQUIRE NOW

SPONSORS

PARTNERS

LOCATION

Venue

Hilton Boston Logan Airport, One Drive, Boston, MA 02128, USA

PAST EVENT GALLERY